
New study to tackle HIV multi-drug resistance launches
In London and Edinburgh, researchers have begun recruiting participants for a new study aimed at better understanding and overcoming HIV multi-drug resistance.
On week one participants will be randomised to one of four blinded arms. Alongside their current, failing, combinations they will receive islatravir, doravirine, both drugs or a placebo.
From week two all participants will receive open-label islatravir and doravirine to an optimised background ART for the next 48 weeks.

28 February 2021 13:17
South Africa eyes up Sputnik vaccine
South African authorities have been working to assess the Russian Sputnik V vaccine this week, reports TASS, citing Bloomberg. The countries health experts and regulators are considering the possibility of using the Russian vaccine for mass vaccination in ...
More

28 February 2021 13:05
UN to host high-level meeting on HIV & AIDS
The United Nations will host a high-level Meeting on HIV & AIDS from 8-10 June 2021 according to the UNAIDS website. During the event world leaders will come together to discuss the five-year results of their combined work to reduce the impact of HIV. The ...
More
About Life4me+
One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis. So we talk about HIV and other diseases: how to protect yourself from them, how to live with them.
More


Campaign U=U (#UequalsU)
The information and education campaign "U=U" ("Undetectable equals untransmittable", #UequalsU, #НравноН), organized by Life4me + in the Eastern Europe and Central Asia region, aimed at disseminating information that an HIV-positive person with an undetectable viral load can not transmit the virus to another person sexually.
Many studies have shown that in a sero-discordant couple where the HIV-positive partner took ARV therapy and maintained an undetectable viral load, there were no reported cases of sexual transmission of HIV.
Our Partners